In 2015, the U.S. Food and Drug Administration approved the first drug with cannabidiol (CBD) for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. CBD is a natural component of the Cannabis Sativa, which does not cause intoxication that comes from tetrahydrocannabinol (THC).
In a randomised, double-blind, placebo-controlled trial done at 24 clinical sites in the USA, the Netherlands, and Poland, the efficacy of cannabidiol was investigated as add-on therapy for drop seizures in patients aged 2–55 years with treatment-resistant Lennox-Gastaut syndrome. According to research that has been printed in the prestigious medical journal The Lancet, “cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated.”  During the 14-week treatment period with cannabidiol, the median percentage reduction in monthly drop seizure frequency was 44%.
Research suggests that cannabidiol is safe and effective add-on therapy for the treatment of epilepsy and helps to improve the quality of life.